Printer Friendly

New biomarker for cervical cancer.

Researchers at the University of North Carolina at Chapel Hill are conducting a study to evaluate a new biomarker for improving cervical cancer screening, according to Genomics & Genetics Weekly. The clinical trial will examine cervical smears for telomerase, a protein released into cells when chromosomes become genetically unstable. The protein's presence in cervical cells removed during Pap smear testing may help predict which women are at greatest risk for developing cervical cancer. The Pap test results in more than 2.5 million abnormal smears in the U.S. each year, but only a small number of those (less than 1%) represent invasive lesions.
COPYRIGHT 1999 Nelson Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Medical Laboratory Observer
Article Type:Brief Article
Geographic Code:1USA
Date:Dec 1, 1999
Previous Article:New biochip to identify TB.
Next Article:PSA as a natural defense.

Related Articles
Long-term pill use, high parity raise cervical cancer risk among women with human papillomavirus infection. (Digests).
More HPV types linked to cervical cancer. (News).
Relative risk of cervical cancer rises with duration of oral contraceptive use.
Increasing organizational capacity for breast and cervical cancer screening of AAPI women.
Pap plus HPV screens save lives.
Merck backs off campaign to make cervical cancer vaccination school entry requirement for preteen girls.
Report: N.H. 'good' at preventing cervical cancer.
January is cervical cancer awareness month.
Encouraging young women to have regular smear tests: nurses must do more to encourage younger women to enrol in the national cervical screening...
Correction to smoking article.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters